A co-infection model for Oncogenic HPV and TB with Optimal Control and Cost-Effectiveness Analysis

A. Omame^a, D. Okuonghae^{b,†}

Abstract

A co-infection model for oncogenic Human papillomavirus (HPV) and Tuberculosis (TB), with optimal control and cost-effectiveness analysis is studied and analyzed to assess the impact of controls against incident infection and against infection with HPV by TB infected individuals as well as optimal TB treatment in reducing the burden of the co-infection of the two diseases in a population. The co-infection model is shown to exhibit the dynamical property of backward bifurcation when the associated reproduction number is less than unity. Furthermore, it is shown that TB and HPV re-infection parameters ($\varphi_p \neq 0$ and $\sigma_t \neq 0$) as well as TB exogenous re-infection term ($\varepsilon_1 \neq 0$) induced the phenomenon of backward bifurcation in the oncogenic HPV-TB co-infection model. The global asymptotic stability of the disease-free equilibrium of the co-infection model is also proven **not to exist**, when the associated reproduction number is below unity. The necessary conditions for the existence of optimal control and the optimality system for the co-infection model is established using the Pontryagin's Maximum Principle. Uncertainty and global sensitivity analysis are also carried out to determine the top ranked parameters that drive the dynamics of the co-infection model, when the associated reproduction numbers as well as the infected populations are used as response functions. Numerical simulations of the optimal control model reveal that the intervention strategy which combines and implements control against HPV infection by TB infected individuals as well as TB treatment control for dually infected individuals is the most cost-effective of all the control strategies for the control and management of the burden of oncogenic HPV and TB co-infection.

Keywords: Human Papillomavirus, tuberculosis, co-infection, optimal control, cost-effectiveness analysis.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

^a Department of Mathematics, Federal University of Technology, Owerri, Nigeria

^b Department of Mathematics, University of Benin, Benin City, Nigeria

[†] Corresponding author: daniel.okuonghae@uniben.edu; danny.okuonghae@corpus-christi.oxon.org

1 Introduction

Tuberculosis (TB), caused by *Mycobacterium tuberculosis* (MTB), remains a global dominant cause of mortality and morbidity, although treatment and preventive measures are available [24, 38]. Globally, TB is one of the dominant cause of mortality from a single infectious disease agent, responsible for roughly 40% of deaths [36]. Worldwide, approximately, 10 million new cases of TB and about 1.57 million TB-induced deaths were reported in 2017, with incidence and mortality highest in South-Eastern Asia and Africa[36]. Estimates have equally shown that about one-fourth of the world’s population is infected with latent TB and is at the risk of progression to active TB [15].

Cancer is the major cause of mortality in developed countries in Europe and America and the second leading cause of death in developing countries [12]. Epidemiological evidences have proven that 80% of global cancer cases are attributed to the oncogenic Human papillomavirus (HPV) [2]. In a study carried out by Zetola *et al.* [37], it was revealed that prior TB infection is mostly common among patients with cases of cervical cancer. Likewise, Zhao *et al* [39], in another study, showed that TB infection is associated with high vulnerability to oncogenic HPV infection. According to Zetola *et al.* [37], oncogenic HPV and tuberculosis always co-exist, and the immune suppression caused by cancer (which is a consequence of oncogenic HPV) can result in latent TB re-activation, hence, leading to high mortality. In addition, persistent gynecologic TB infection, resulting in chronic inflammation, could be a high risk factor in the progression of oncogenic HPV infection to cervical cancer [37, 39].

Mathematical models have recently been studied to understand the transmission dynamics of human papillomavirus infection (See Oname et al. [23] and the references included therein). Malik *et al.* [17] investigated an optimal control model for HPV, incorporating optimal vaccination strategies for females in the population. In particular, they considered when three vaccines are used at the same time in comparison to the case where the bivalent *cervarix* and quadrivalent *Gardasil 4* vaccines were used at the initial stage and then, during the course of the vaccination program, one or two of them are interchanged with the nonavalent *Gardasil 9* vaccine. Saldana *et al.* [29] developed and analyzed a two-sex model of HPV with optimal control analysis, incorporating vaccination of adolescents, adults, and screening. They showed that to optimally curb the spread of HPV in a population, vaccination should be administered both before and after the commencement of active sexual life for both females and males in the population. Likewise, TB only models have been extensively studied in the literature (see for instance, [10, 21, 22, 33] and many others).

Lately, mathematical models have been developed to consider the optimal control strategies for the dynamics of infectious diseases including their co-infections [1, 9, 11, 20, 26, 27, 31, 32, 34]. Agosto and Adekunle [1] studied the optimal control and cost-effectiveness analysis of the co-infection of drug-resistant tuberculosis and HIV/AIDS. They considered different control strategies for the control of the co-infections of both diseases. They showed that the strategy which combines efforts on minimizing the number of individuals with drug-sensitive and drug-resistant TB and case finding, prevention

of treatment failure in the drug-sensitive TB infectious individuals and the treatment of individuals with drug-resistant TB is the most cost-effective in curbing the co-infections of drug-resistant TB and HIV/AIDS. Okosun and Makinde [20] considered a malaria-cholera co-infection model, in the presence of prevention and treatment controls for both diseases. Applying the Pontryagin's Maximum principle, they derived the necessary conditions for optimality and equally showed using simulations, that to successfully curb malaria spread, control strategies must include cholera intervention strategies as well. Tilahun *et al.* [32] investigated a Pneumonia-Typhoid co-infection model with cost-effective optimal control analysis, incorporating preventive and treatment controls for both diseases. They showed that the strategy that combines Pneumonia treatment and Typhoid fever prevention is the most cost-effective in reducing the burden of the co-infections of Pneumonia and Typhoid fever. The researchers in [9] analyzed an optimal control model for HIV and TB co-infection, capturing resistance of HIV to anti-retroviral therapy. The authors showed that a combination of TB treatment and anti-retroviral therapy for HIV is the most effective in reducing the burden of the co-infection of the two diseases. In addition, Tanvi and Aggarwal [31] studied an HIV-TB co-infection, incorporating detection and treatment for both diseases. They observed that the strategy that implements detection for both diseases yielded the most economic and epidemic gains in fighting the co-infections of the two diseases.

To the best of the authors' knowledge, optimal control analysis has never been applied to the co-infection of Human papillomavirus and TB in the literature. Hence, it will be imperative to investigate the optimal control and cost-effectiveness analysis of the co-infections of oncogenic HPV and TB. In particular, this paper extends the work of Omame *et al.* [24] by assessing the impact of HPV prevention and TB treatment controls on the control and management of the co-infections of the two diseases.

The rest of the paper is organized as follows. The model is formulated in Section 2, alongside the basic properties of the model. The co-infection model without controls is analyzed qualitatively in Section 3. The optimal control model is considered in Section 4. Simulations of the model are carried out in Section 5 while Section 6 gives the concluding remarks.

2 Model formulation and basic properties of the model

The total sexually active population at time t , denoted by $N_H(t)$, is divided into eleven mutually-exclusive compartments: Susceptible individuals ($S(t)$), individuals infected with HPV ($I_{HP}(t)$), individuals who have recovered from or cleared HPV infection ($R_{HP}(t)$), individuals with persistent HPV infection ($P_{HP}(t)$), individuals with latent TB ($E_T(t)$), individuals with active TB infection ($A_T(t)$), individuals treated of TB ($T_T(t)$), individuals dually infected with HPV and latent TB ($I_{HE}^p(t)$), individuals dually infected with HPV and active TB (I_{HA}^p), individuals dually infected with persistent HPV and latent TB, ($P_{HE}^p(t)$) individuals dually infected with persistent HPV and active ($P_{HA}^p(t)$). Thus

$$N_H = S + I_{HP} + R_{HP} + P_{HP} + E_T + A_T + T_T + I_{HE}^p + I_{HA}^p + P_{HE}^p + P_{HA}^p$$

Based on the above formulations and assumptions, the HPV-TB Coinfection model is given by the following deterministic system of non-linear differential equations (flow diagram of the model is shown in Figure 1, the associated state variables and parameters are well described in Tables 1 and 2):

$$\begin{aligned}
 \frac{dS}{dt} &= \Lambda_H - (\lambda_{HP} + \mu_H + \lambda_T)S \\
 \frac{dI_{HP}}{dt} &= \lambda_{HP}S + r_2^T I_{HA}^P + \lambda_{HP}T_T + \varphi_p \lambda_{HP}R_{HP} - (\phi_1^P + \lambda_T + \mu_H + \delta_{HP})I_{HP} \\
 \frac{dP_{HP}}{dt} &= (1 - \theta_1^P)\phi_1^P I_{HP} + r_3^T P_{HA}^P - (\rho_1^P + \mu_H + \lambda_T)P_{HP} \\
 \frac{dR_{HP}}{dt} &= \theta_1^P \phi_1^P I_{HP} + \rho_1^P P_{HP} - (\varphi_p \lambda_{HP} + \mu_H + \lambda_T)R_{HP} \\
 \frac{dE_T}{dt} &= (1 - \xi_1^T)\lambda_T(S + R_{HP} + \sigma_T T_T) + \theta_2^P \phi_2^P I_{HE}^P + \rho_2^P P_{HE}^P - (\varepsilon_1^T \lambda_T + \gamma_1^T + \varrho_1^P \lambda_{HP} + \mu_H)E_T \\
 \frac{dA_T}{dt} &= \xi_1^T \lambda_T(S + R_{HP} + \sigma_T T_T) + \varepsilon_1^T \lambda_T E_T + \gamma_1^T E_T + \theta_3^P \phi_3^P I_{HA}^P + \rho_3^P P_{HA}^P - (r_1^T + \mu_H + \delta_T + \varrho_2^P \lambda_{HP})A_T \\
 \frac{dT_T}{dt} &= r_1^T A_T - (\sigma_T \lambda_T + \lambda_{HP} + \mu_H)T_T \\
 \frac{dI_{HE}^P}{dt} &= (1 - \xi_2^T)\lambda_T I_{HP} + \varrho_1^P \lambda_{HP} E_T - (\varepsilon_2^T \lambda_T + \gamma_2^T + \mu_H + \phi_2^P + \delta_{HP1})I_{HE}^P \\
 \frac{dI_{HA}^P}{dt} &= \xi_2^T \lambda_T I_{HP} + \varepsilon_2^T \lambda_T I_{HE}^P + \gamma_2^T I_{HE}^P + \varrho_2^P \lambda_{HP} A_T - (r_2^T + \mu_H + \delta_{T1} + \delta_{HP2} + \phi_3^P)I_{HA}^P \\
 \frac{dP_{HE}^P}{dt} &= (1 - \xi_3^T)\lambda_T P_{HP} + (1 - \theta_2^P)\phi_2^P I_{HE}^P - (\varepsilon_3^T \lambda_T + \gamma_3^T + \rho_3^P + \mu_H)P_{HE}^P \\
 \frac{dP_{HA}^P}{dt} &= \xi_3^T \lambda_T P_{HP} + \varepsilon_3^T \lambda_T P_{HE}^P + \gamma_3^T P_{HE}^P + (1 - \theta_3^P)\phi_3^P I_{HA}^P - (r_3^T + \delta_{T2} + \rho_3^P + \mu_H)P_{HA}^P
 \end{aligned} \tag{1}$$

where:

$$\lambda_{HP} = \frac{\beta_{HP}[I_{HP} + \eta_p P_{HP} + \kappa_T(I_{HA}^P + \eta_T I_{HE}^P + \eta_p P_{HA}^P + \eta_T \eta_p P_{HE}^P)]}{N_H}, \tag{2}$$

$$\lambda_T = \frac{\beta_T[A_T + \omega_p(I_{HA}^P + \eta_p P_{HA}^P)]}{N_H} \tag{3}$$

The parameters κ_T ($\kappa_T \geq 1$) is a modification parameter accounting for the increased infectiousness of dually infected individuals due to tuberculosis, η_T ($\eta_T \leq 1$) is a modification parameter accounting for reduced infectiousness of dually infected individuals due to latent TB. ω_p ($\omega_p \geq 1$) is a modification parameter accounting for the increased infectiousness of dually infected individuals due to HPV while η_p ($\eta_p \leq 1$) is a modification parameter accounting for the reduced infectiousness of singly infected and dually infected individuals due to persistent HPV infection. This population is further reduced by natural death (at a rate μ_H natural death occurs in all epidemiological compartments at this rate). In (2), β_{HP} is the effective contact rate for transmission of HPV infection.

Table 1: Description of variables in the model (1).

Variable	Interpretation
S	population of susceptible individuals
I_{HP}	Population of individuals infected with HPV
R_{HP}	Population of individuals who have recovered from HPV
P_{HP}	Population of individuals with persistent HPV infection
E_T	Population of individuals with latent TB
A_T	Population of individuals with active TB
T_T	Population of individuals treated of TB
I_{HE}^P	Population of individuals dually infected with HPV and latent TB
I_{HA}^P	Population of individuals dually infected with HPV and active TB
P_{HE}^P	Population of individuals dually infected with persistent HPV and latent TB
P_{HA}^P	Population of individuals dually infected with persistent HPV and active TB
N_H	Total human population

Table 2: Description of parameters in the model (1).

Parameter	Interpretation	Value	References
Λ_H	Recruitment rate	164490	[8]
μ_H	Natural death rate	0.0128	[8]
ϕ_i^P $i=1,2,3$	Recovery rates from HPV for individuals in the I_{HP} , I_{HE}^P , I_{HA}^P classes, respectively	0.9	[16]
r_i^T $i=1,2,3$	Recovery rates from TB for individuals in the A_T , I_{HA}^P , P_{HA}^P classes	2.0	[24]
θ_i^P $i=1,2,3$	Fraction of infected individuals who recovered naturally from HPV (but did not develop persistent HPV infection)	0.5	[16]
ρ_i^P $i=1,2,3$	Rate at which individuals recover naturally from the persistent infection	0.895	[24]
φ_P	Rate of reinfection with HPV	0.2	[25]
δ_{HP}	Disease induced death rates for individuals singly infected with HPV	0.001	[16, 25]
δ_T	Disease induced death rates for individuals singly infected with tuberculosis	0.07	[21]
δ_{T1}, δ_{T2}	TB-induced death rates for individuals dually infected with active tuberculosis and HPV	0.007	[21]
$\delta_{HP1}, \delta_{HP2}$	HPV-induced death rates for mixed infections	0.001	[24]
σ_T	Rate of reinfection with TB	0.2	[24]
ξ_i^T $i=1,2,3$	Fraction of newly infected individuals with active TB	0.7	[24]
ε_1^T	Exogenous re-infection rates to active TB	1.5	[22]
ε_i^T $i=2,3$	Exogenous re-infection rates to active TB for individuals with mixed infections	1.5	Assumed
γ_1^T	Slow progression rate to active TB	0.005	[7]
γ_i^P $i=2,3$	Slow progression rate to active TB for individuals with mixed infections	0.005	Assumed
β_{HP}	Effective contact rate for HPV transmission	1.0	[16]
β_T	Effective contact rate for TB transmission	8.557	[22]
η_T	Modification parameter for reduced infectiousness of dually infected individuals with latent TB relative to those with active TB	0.9	Assumed
ω_P	Modification parameter for increased infectiousness of dually infected individuals due to HPV	1.2	Assumed
η_P	Modification parameter for reduced infectiousness of infected individuals with persistent HPV relative to those infected with HPV	0.9	[23]
ϱ_1^P	Modification parameter accounting for increased susceptibility to HPV by TB infected individuals	1.3	[39]
ϱ_2^P	Modification parameter accounting for increased susceptibility to HPV by TB infected individuals with mixed infections	1.3	[39]

2.1 Basic properties of the co-infection model (1) without controls

The basic qualitative properties of the oncogenic HPV-TB co-infection model (1) will now be considered. Specifically, we establish the following results.

2.1.1 Positivity and boundedness of solutions

For the oncogenic HPV-TB co-infection model (1) to be meaningful in the concept of epidemiological sense, it is necessary to prove that all its state variables are non-negative over time. The approach adopted by Oname *et al* [23] will be used to establish the results below.

Theorem 2.1 *Let the initial data be*

$$S(0) > 0, I_{HP}(0) \geq 0, R_{HP}(0) \geq 0, P_{HP}(0) \geq 0, E_T(0) \geq 0, A_T(0) \geq 0, T_T(0) \geq 0, I_{HE}^p(0) \geq 0, I_{HA}^p(0) \geq 0, P_{HE}^p(0) \geq 0, P_{HA}^p(0) \geq 0$$

Then the solutions

$(S, I_{HP}, R_{HP}, P_{HP}, E_T, A_T, T_T, I_{HE}^p, I_{HA}^p, P_{HE}^p, P_{HA}^p)$ of the model (1) are non-negative for all time $t > 0$.

Lemma 2.1 *The region $\mathcal{D} \subset \mathfrak{R}_+^{11}$ is positively-invariant for the co-infection model (1) with initial conditions in $\mathfrak{R}_+^{11}$.*

3 Mathematical Analysis of the model without controls

3.1 Basic reproduction number of the co-infection model

The co-infection model (1) has a DFE, obtained by setting the right-hand sides of the equations in the model (1) to zero, given by

$$\begin{aligned} \xi_0 = & (S^*, I_{HP}^*, P_{HP}^*, R_{HP}^*, E_T^*, A_T^*, T_T^*, I_{HE}^{p*}, I_{HA}^{p*}, P_{HE}^{p*}, P_{HA}^{p*}) \\ = & \left(\frac{\Lambda_H}{\mu_H}, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 \right) \end{aligned} \quad (4)$$

The basic reproduction number of the oncogenic HPV-TB co-infection model (1), using the approach in van den Driessche and Watmough [35], is given by $\mathcal{R}_0 = \max\{\mathcal{R}_{0H}, \mathcal{R}_{0T}\}$ where $\mathcal{R}_{0H}$ and $\mathcal{R}_{0T}$ are, respectively, the oncogenic HPV and TB associated reproduction numbers, given by

$$\mathcal{R}_{0H} = \frac{\beta_{HP}(\Delta_2 + \eta_P \varpi_1)}{\Delta_1 \Delta_2}$$

and

$$\mathcal{R}_{0T} = \frac{\beta_T[\gamma_1^T(1 - \xi_1^T) + \xi_1^T \Delta_3]}{\Delta_3 \Delta_4}$$

Figure 1: Schematic diagram of the model (1)

where,

$$\Delta_1 = \phi_1^p + \delta_{HP} + \mu_H, \quad \Delta_2 = \rho_1^p + \mu_H, \quad \Delta_3 = \gamma_1^T + \mu_H, \quad \Delta_4 = r_1^T + \delta_T + \mu_H, \quad \varpi_1 = (1 - \theta_1^p)\phi_1^p$$

Using Theorem 2 of [35], the following result is established.

Lemma 3.1 *The DFE, ξ_0 , of the oncogenic HPV-TB co-infection model (1) is locally asymptotically stable if $\mathcal{R}_0 < 1$, and unstable if $\mathcal{R}_0 > 1$.*

3.2 Global asymptotic stability(GAS) of the disease-free equilibrium(DFE) ξ_0 of the co-infection model

We shall apply the approach illustrated in [5] to investigate the global asymptotic stability of the disease free equilibrium of the co-infection model. In this section, we list two conditions that if met, also guarantee the global asymptotic stability of the disease-free state. First, system (1) must be written in the form:

$$\begin{aligned} \frac{dV}{dt} &= P(V, K) \\ \frac{dK}{dt} &= Q(V, K), Q(V, 0) = 0 \end{aligned} \quad (5)$$

where $V \in R^m$ denotes (its components) the number of uninfected individuals and $K \in R^n$ denotes (its components) the number of infected individuals. $U_0 = (V^*, 0)$ denotes the disease-free equilibrium of this system. The conditions (W1) and (W2) following must be satisfied in order to guarantee local asymptotic stability:

(W1): For $\frac{dV}{dt} = P(V, 0)$, V^* is globally asymptotically stable (GAS),

(W2): $Q(V, K) = BK - \hat{Q}(V, K)V$, $Q(V, K) \geq 0$ for $(V, K) \in \Omega$,

where $B = D_K Q(V^*, 0)$ is an M-matrix (the off-diagonal elements of B are nonnegative) and Ω is the region where the model makes biological sense. If System (1) satisfies the above two conditions then the following theorem holds:

Theorem 3.1 *The fixed point $U_0 = (V^*, 0)$ is a globally asymptotic stable (GAS) equilibrium of (1) provided that $R_0 < 1$ (LAS) and that assumptions (W1) and (W2) are met*

Proof

$$\frac{dV}{dt} = P(V, K) = \begin{pmatrix} \Lambda_H - (\lambda_{HP} + \mu_H + \lambda_T)S \\ \theta_1^p \phi_1^p I_{HP} + \rho_1^p P_{HP} - (\varphi_p \lambda_{HP} + \mu_H + \lambda_T)R_{HP} \\ r_1^T A_T - (\sigma_T \lambda_T + \lambda_{HP} + \mu_H)T_T \end{pmatrix}, \quad (6)$$

$$P(V, 0) = \begin{pmatrix} \Lambda_H - \mu_H S \\ 0 \\ 0 \end{pmatrix} \quad (7)$$

where V denotes the number of non-infectious compartments and K denotes the number of infectious compartments

$$Q(V, K) = \begin{pmatrix} \lambda_{HP} S + r_2^T I_{HA}^P + \lambda_{HP} T_T + \varphi_P \lambda_{HP} R_{HP} - (\phi_1^P + \lambda_T + \mu_H + \delta_{HP}) I_{HP} \\ (1 - \theta_1^P) \phi_1^P I_{HP} + r_3^T P_{HA}^P - (\rho_1^P + \mu_H + \lambda_T) P_{HP} \\ (1 - \xi_1^T) \lambda_T (S + R_{HP} + \sigma_T T_T) + \theta_2^P \phi_2^P I_{HE}^P + \rho_2^P P_{HE}^P - (\varepsilon_1^T \lambda_T + \gamma_1^T + \varrho_1^P \lambda_{HP} + \mu_H) E_T \\ \xi_1^T \lambda_T (S + R_{HP} + \sigma_T T_T) + \varepsilon_1^T \lambda_T E_T + \gamma_1^T E_T + \theta_3^P \phi_3^P I_{HA}^P + \rho_3^P P_{HA}^P - (r_1^T + \mu_H + \delta_T + \varrho_2^P \lambda_{HP}) A_T \\ (1 - \xi_2^T) \lambda_T I_{HP} + \varrho_1^P \lambda_{HP} E_T - (\varepsilon_2^T \lambda_T + \gamma_2^T + \mu_H + \phi_2^P + \delta_{HP1}) I_{HE}^P \\ \xi_2^T \lambda_T I_{HP} + \varepsilon_2^T \lambda_T I_{HE}^P + \gamma_2^T I_{HE}^P + \varrho_2^P \lambda_{HP} A_T - (r_2^T + \mu_H + \delta_{T1} + \delta_{HP2} + \phi_3^P) I_{HA}^P \\ (1 - \xi_3^T) \lambda_T P_{HP} + (1 - \theta_2^P) \phi_2^P I_{HE}^P - (\varepsilon_3^T \lambda_T + \gamma_3^T + \rho_3^P + \mu_H) P_{HE}^P \\ \xi_3^T \lambda_T P_{HP} + \varepsilon_3^T \lambda_T P_{HE}^P + \gamma_3^T P_{HE}^P + (1 - \theta_3^P) \phi_3^P I_{HA}^P - (r_3^T + \delta_{T2} + \rho_3^P + \mu_H) P_{HA}^P \end{pmatrix},$$

$$B = D_K Q(V^*, 0) = \begin{pmatrix} \beta_{HP} - \Delta_1 & \beta_{HP} \eta_P & 0 & 0 & \beta_{HP} \kappa_T \eta_T & \beta_{HP} \kappa_T + r_2^T & \beta_{HP} \kappa_T \eta_T \eta_P & \beta_{HP} \kappa_T \eta_T \\ \varpi_1 & -\Delta_2 & 0 & 0 & 0 & 0 & 0 & r_3^T \\ 0 & 0 & -\Delta_3 & (1 - \xi_1^T) \beta_T & \theta_2^P \phi_2^P & (1 - \xi_1^T) \beta_T \omega_P & \rho_2^P & (1 - \xi_1^T) \beta_T \omega_P \eta_P \\ 0 & 0 & \gamma_1^P & \xi_1^T \beta_T - \Delta_4 & 0 & \xi_1^T \beta_T \omega_P + \theta_3^P \phi_3^P & 0 & \xi_1^T \beta_T \omega_P \eta_P + \rho_3^P \\ 0 & 0 & 0 & 0 & -\Delta_5 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & \gamma_2^T & -\Delta_6 & 0 & 0 \\ 0 & 0 & 0 & 0 & \varpi_2 & 0 & -\Delta_7 & 0 \\ 0 & 0 & 0 & 0 & 0 & \varpi_3 & \gamma_3^T & -\Delta_8 \end{pmatrix}$$

$$\hat{Q}(V, K) = \begin{pmatrix} \beta_{HP} [I_{HP} + \eta_P P_{HP} + \kappa_T (I_{HA}^P + \eta_T I_{HE}^P + \eta_P P_{HA}^P + \eta_T \eta_P P_{HE}^P)] (1 - \frac{S+T}{N}) - \varphi_P \lambda_{HP} R_{HP} + \lambda_T I_{HP} \\ \lambda_T P_{HP} \\ (1 - \xi_1^T) \beta_T [A_T + \omega_P (I_{HA}^P + \eta_P P_{HA}^P)] (1 - \frac{S+R_{HP}}{N}) - (1 - \xi_1^T) \lambda_T \sigma_T T_T + \varepsilon_1^T \lambda_T E_T + \varrho_1^P \lambda_{HP} E_T \\ \xi_1^T \beta_T [A_T + \omega_P (I_{HA}^P + \eta_P P_{HA}^P)] (1 - \frac{S+R_{HP}}{N}) - \xi_1^T \lambda_T \sigma_T T_T - \varepsilon_1^T \lambda_T E_T + \varrho_2^P \lambda_{HP} A_T \\ -(1 - \xi_2^T) \lambda_T I_{HP} - \varrho_1^P \lambda_{HP} E_T + \varepsilon_2^T \lambda_T I_{HE}^P \\ -\xi_2^T \lambda_T I_{HP} - \varrho_2^P \lambda_{HP} A_T - \varepsilon_2^T \lambda_T I_{HE}^P \\ -(1 - \xi_3^T) \lambda_T P_{HP} + \varepsilon_3^T \lambda_T P_{HE}^P \\ -\xi_3^T \lambda_T P_{HP} - \varepsilon_3^T \lambda_T P_{HE}^P \end{pmatrix}$$

It is clear from the above, that, $\hat{Q}(V, K) \not\leq 0$. Hence the DFE may not be globally asymptotically stable, suggesting the possibility of a backward bifurcation. This supports the backward bifurcation analysis in the proceeding section.

3.3 Backward bifurcation analysis of the model without controls

We shall carry out analysis in this section to know the type of bifurcation the model (1) may undergo, using the Centre Manifold Theory as illustrated in [6]. The following result can be established.

Theorem 3.2 Suppose a backward bifurcation coefficient $a > 0$, (with a defined below), when $\mathcal{R}_0 < 1$

$$a = -\frac{2\beta_{\text{HP}}^*}{N_{\text{H}}^*}(\omega_2 + \eta_{\text{r}}\omega_3)\{(\omega_2 + \omega_3 + \omega_4 + \omega_5 + \omega_6)\nu_2 + (\nu_5 + \nu_8)\varrho_1^{\text{p}}\omega_5 + (\nu_6 + \nu_9)\varrho_2^{\text{p}}\omega_6 - \varphi_{\text{r}}\omega_4\} \\ - \frac{2\beta_{\text{T}}\nu_5(1 - \xi_1^{\text{T}})\omega_6}{N_{\text{H}}^*}(\omega_2 + \omega_3 + \omega_5 + \omega_6 + \omega_7 + \varepsilon_1^{\text{T}}\omega_5 - \sigma_{\text{T}}\omega_7) - \frac{2\beta_{\text{T}}\nu_6\xi_1^{\text{T}}\omega_6}{N_{\text{H}}^*}(\omega_2 + \omega_3 + \omega_5 + \omega_6 + \omega_7 - \varepsilon_1^{\text{T}}\omega_5 - \sigma_{\text{T}}\omega_7) \\ - \frac{2\beta_{\text{T}}\omega_6}{N_{\text{H}}^*}\{\nu_2\omega_2 + \nu_3\omega_3 + [(1 - \xi_2^{\text{T}})\nu_8 - \xi_1^{\text{T}}\nu_9]\omega_2 + [(1 - \xi_3^{\text{T}})\nu_{10} - \xi_3^{\text{T}}\nu_{11}]\omega_3\}$$

then model (1) exhibits backward bifurcation at $\mathcal{R}_0 = 1$. If $a < 0$, then the system (1) exhibits a forward bifurcation at $\mathcal{R}_0 = 1$.

Proof

Suppose

$$\xi_e = (S^{**}, I_{\text{HP}}^{**}, P_{\text{HP}}^{**}, R_{\text{HP}}^{**}, E_{\text{T}}^{**}, A_{\text{T}}^{**}, T_{\text{T}}^{**}, I_{\text{HE}}^{**}, I_{\text{HA}}^{**}, P_{\text{HE}}^{**}, P_{\text{HA}}^{**})$$

represents any arbitrary endemic equilibrium of the model. The existence of backward bifurcation will be studied using the Centre Manifold Theory [6]. To apply this theory, it is appropriate to do the following change of variables.

Let

$$S = x_1, I_{\text{HP}} = x_2, P_{\text{HP}} = x_3, R_{\text{HP}} = x_4, E_{\text{T}} = x_5, A_{\text{T}} = x_6, T_{\text{T}} = x_7, I_{\text{HE}} = x_8, I_{\text{HA}} = x_9, P_{\text{HE}} = x_{10}, P_{\text{HA}} = x_{11}$$

so that

$$N_{\text{H}} = \sum_{i=1}^{11} x_i$$

Further, using the vector notation

$$X = (x_1, x_2, x_3, x_4, x_5, x_6, x_7, x_8, x_9, x_{10}, x_{11})^T$$

the model (1) can be re-written in the form

$$\frac{dX}{dt} = f = (f_1, f_2, f_3, f_4, f_5, f_6, f_7, f_8, f_9, f_{10}, f_{11})^T$$

as follows:

$$\begin{aligned}
 \frac{dx_1}{dt} &= \Lambda_H - (\lambda_{HP} + \mu_H + \lambda_T)x_1 := f_1 \\
 \frac{dx_2}{dt} &= \lambda_{HP}x_1 + r_2^T x_9 + \lambda_{HP}x_7 + \varphi_P \lambda_{HP}x_4 - (\phi_1^P + \lambda_T + \mu_H + \delta_{HP})x_2 := f_2 \\
 \frac{dx_3}{dt} &= (1 - \theta_1^P)\phi_1^P x_2 + r_3^T x_{11} - (\rho_1^P + \mu_H + \lambda_T)x_3 := f_3 \\
 \frac{dx_4}{dt} &= \theta_1^P \phi_1^P x_2 + \rho_1^P x_3 - (\varphi_P \lambda_{HP} + \mu_H + \lambda_T)x_4 := f_4 \\
 \frac{dx_5}{dt} &= (1 - \xi_1^T)\lambda_T(x_1 + x_4 + \sigma_T x_7) + \theta_2^P \phi_2^P x_8 + \rho_2^P x_{10} - (\varepsilon_1^T \lambda_T + \gamma_1^T + \varrho_1^P \lambda_{HP} + \mu_H)x_5 := f_5 \\
 \frac{dx_6}{dt} &= \xi_1^T \lambda_T(x_1 + x_4 + \sigma_T x_7) + \varepsilon_1^T \lambda_T x_5 + \gamma_1^T x_5 + \theta_3^P \phi_3^P x_9 + \rho_3^P x_{11} - (r_1^T + \mu_H + \delta_T + \varrho_2^P \lambda_{HP})x_6 := f_6 \\
 \frac{dx_7}{dt} &= r_1^T x_6 - (\sigma_T \lambda_T + \lambda_{HP} + \mu_H)x_7 := f_7 \\
 \frac{dx_8}{dt} &= (1 - \xi_2^T)\lambda_T x_2 + \varrho_1^P \lambda_{HP} x_5 - (\varepsilon_2^T \lambda_T + \gamma_2^T + \mu_H + \phi_2^P + \delta_{HP1})x_8 := f_8 \\
 \frac{dx_9}{dt} &= \xi_2^T \lambda_T x_2 + \varepsilon_2^T \lambda_T x_8 + \gamma_2^T x_8 + \varrho_2^P \lambda_{HP} x_6 - (r_2^T + \mu_H + \delta_{T1} + \delta_{HP2} + \phi_3^P)x_9 := f_9 \\
 \frac{dx_{10}}{dt} &= (1 - \xi_3^T)\lambda_T x_3 + (1 - \theta_2^P)\phi_2^P x_8 - (\varepsilon_3^T \lambda_T + \gamma_3^T + \rho_3^P + \mu_H)x_{10} := f_{10} \\
 \frac{dx_{11}}{dt} &= \xi_3^T \lambda_T x_3 + \varepsilon_3^T \lambda_T x_{10} + \gamma_3^T x_{10} + (1 - \theta_3^P)\phi_3^P x_9 - (r_3^T + \delta_{T2} + \rho_3^P + \mu_H)x_{11} := f_{11}
 \end{aligned} \tag{8}$$

with:

$$\begin{aligned}
 \lambda_{HP} &= \frac{\beta_{HP}[x_2 + \eta_P x_3 + \kappa_T(x_9 + \eta_T x_8 + \eta_P x_{11} + \eta_T \eta_P x_{10})]}{\sum_{i=1}^{11} x_i}, \\
 \lambda_T &= \frac{\beta_T[x_6 + \omega_P(x_9 + \eta_P x_{11})]}{\sum_{i=1}^{11} x_i}
 \end{aligned}$$

Consider the case when $\mathcal{R}_{0H} = 1$. Assume, further, that β_{HP} is chosen as a bifurcation parameter. Solving for $\beta_{HP} = \beta_{HP}^*$ from $\mathcal{R}_{0H} = 1$ gives

$$\beta_{HP} = \beta_{HP}^* = \frac{\Delta_1 \Delta_2}{(\Delta_2 + \eta_P \varpi_1)}$$

Evaluating the Jacobian of the system (8) at the DFE, $J(\xi_0)$, and using the approach in [6], we have that $J(\xi_0)$ has a right eigenvector (associated with the simple zero eigenvalue) given by

$$\mathbf{w} = [\omega_1, \omega_2, \omega_3, \omega_4, \omega_5, \omega_6, \omega_7, \omega_8, \omega_9, \omega_{10}, \omega_{11}]^T$$

where,

$$\begin{aligned}
 \omega_1 &= -\frac{1}{\mu_H} (\beta_{HP}^* \omega_2 + \beta_{HP}^* \eta_P \omega_3 + \beta_T) < 0, \\
 \omega_2 &= \omega_2 > 0, \\
 \omega_3 &= \frac{\varpi_1 \omega_2}{\Delta_2} > 0, \\
 \omega_4 &= \frac{\theta_1^P \phi_1^P \omega_2 + \rho_1^P \omega_3}{\mu_H} > 0, \\
 \omega_5 &= \frac{(1 - \xi_1^T) \beta_T \omega_6}{\Delta_3} > 0 \\
 \omega_6 &= \omega_6 > 0 \\
 \omega_7 &= \frac{r_1^T \omega_6}{\mu_H} \\
 \omega_8 &= \omega_9 = \omega_{10} = \omega_{11} = 0
 \end{aligned} \tag{9}$$

The components of the left eigenvector of $J(\xi_0)|_{\beta_S=\beta_S^*}$, $\mathbf{v} = (\nu_1, \nu_2, \dots, \nu_{11})$, satisfying $\mathbf{v} \cdot \mathbf{w} = 1$ are

$$\begin{aligned}
 \nu_2 &= \nu_2 > 0 \\
 \nu_3 &= \frac{\beta_{HP}^* \eta_P \nu_2}{\Delta_2} > 0 \\
 \nu_5 &= \frac{\gamma_1^T \nu_6}{\Delta_3} > 0 \\
 \nu_6 &= \nu_6 > 0 \\
 \nu_8 &= \frac{\beta_{HP}^* \kappa_T \eta_T \nu_2 + \theta_2^P \phi_2^P \nu_5 + \gamma_2^T \nu_9 + \varpi_2 \nu_{10}}{\Delta_5} > 0 \\
 \nu_9 &= \frac{(\beta_{HP}^* \kappa_T + r_2^T) \nu_2 + (1 - \xi_1^T) \beta_T \omega_P \nu_5 + (\xi_1^T \beta_T \omega_P + \theta_3^P \phi_1^P) \nu_6 + \varpi_3 \nu_{11}}{\Delta_6} > 0 \\
 \nu_{10} &= \frac{\beta_{HP}^* \kappa_T \eta_T \eta_P \nu_2 + \rho_2^P \nu_5 + \gamma_3^T \nu_{11}}{\Delta_7} > 0 \\
 \nu_{11} &= \frac{\beta_{HP}^* \kappa_T \eta_P \nu_2 + r_3^T \nu_3 + (1 - \xi_1^T) \beta_T \omega_P \eta_P \nu_5 + (\xi_1^T \beta_T \omega_P \eta_P + \rho_3^P) \nu_6}{\Delta_6} > 0 \\
 \nu_1 &= \nu_4 = \nu_7 = 0.
 \end{aligned} \tag{10}$$

where,

$$\begin{aligned}
 \Delta_1 &= \phi_1^P + \delta_{HP} + \mu_H, \quad \Delta_2 = \rho_1^P + \mu_H, \quad \Delta_3 = \gamma_1^T + \mu_H, \quad \Delta_4 = r_1^T + \delta_T + \mu_H, \quad \Delta_5 = \gamma_2^T + \mu_H + \phi_2^P + \delta_{HP1}, \\
 \Delta_6 &= r_2^T + \delta_{T1} + \delta_{HP2} + \phi_3^P + \mu_H, \quad \Delta_7 = \gamma_3^T + \rho_3^P + \mu_H, \quad \Delta_8 = r_3^T + \delta_{T2} + \rho_3^P + \mu_H, \quad \varpi_1 = (1 - \theta_1^P) \phi_1^P, \\
 \varpi_2 &= (1 - \theta_2^P) \phi_2^P, \quad \varpi_3 = (1 - \theta_3^P) \phi_3^P
 \end{aligned}$$

The associated bifurcation coefficients defined by a and b , given by:

$$a = \sum_{k,i,j=1}^n \nu_k \omega_i \omega_j \frac{\partial^2 f_k}{\partial x_i \partial x_j}(0,0) \quad \text{and} \quad b = \sum_{k,i=1}^n \nu_k \omega_i \frac{\partial^2 f_k}{\partial x_i \partial \beta_S^*}(0,0),$$

are computed to be

$$\begin{aligned}
 a &= -\frac{2\beta_{HP}^*}{N_H^*} (\omega_2 + \eta_P \omega_3) \{ (\omega_2 + \omega_3 + \omega_4 + \omega_5 + \omega_6) \nu_2 + (\nu_5 + \nu_8) \varrho_1^P \omega_5 + (\nu_6 + \nu_9) \varrho_2^P \omega_6 - \varphi_P \omega_4 \} \\
 &\quad - \frac{2\beta_T \nu_5 (1 - \xi_1^T) \omega_6}{N_H^*} (\omega_2 + \omega_3 + \omega_5 + \omega_6 + \omega_7 + \varepsilon_1^T \omega_5 - \sigma_T \omega_7) - \frac{2\beta_T \nu_6 \xi_1^T \omega_6}{N_H^*} (\omega_2 + \omega_3 + \omega_5 + \omega_6 + \omega_7 - \varepsilon_1^T \omega_5 - \sigma_T \omega_7) \\
 &\quad - \frac{2\beta_T \omega_6}{N_H^*} \{ \nu_2 \omega_2 + \nu_3 \omega_3 + [(1 - \xi_2^T) \nu_8 - \xi_1^T \nu_9] \omega_2 + [(1 - \xi_3^T) \nu_{10} - \xi_3^T \nu_{11}] \omega_3 \}
 \end{aligned} \tag{11}$$

and

$$b = \sum_{k,i=1}^{20} \nu_k \omega_i \frac{\partial^2 f_k}{\partial x_i \partial \beta^*}(0,0) = (\omega_2 + \eta_p \omega_3) \nu_2 > 0$$

Since the bifurcation coefficient b is positive, it follows from Theorem 4.1 in [6] that the model (1), or the transformed model (8), will undergo a backward bifurcation if the backward bifurcation coefficient, a , given by (11) is positive. Setting the HPV and TB re-infection parameters $\varphi_p = 0, \sigma_T = 0$ and the TB exogenous re-infection term $\varepsilon_1^T = 0$, the bifurcation coefficient, $a < 0$ (since $(1 - \xi_2^T) \nu_8 > \xi_2^T \nu_9 > 0$ and $(1 - \xi_3^T) \nu_{10} > \xi_3^T \nu_{11} > 0$, based on the definition of the components in (9), and also noting that all other components of the left and right eigenvectors occurring in the coefficient, a , are positive, including the parameters of the model. Hence, backward bifurcation does not occur in the Oncogenic HPV-TB co-infection model, in the absence of HPV and TB re-infection and in the absence of exogenous re-infection. $\square$

4 Optimal control model

In this section, we shall use the Pontryagin's Maximum Principle to determine the necessary conditions for the optimal control of the oncogenic HPV-TB co-infection model. We incorporate time dependent controls into the model (1) to determine the optimal strategy for curbing the co-infections of the two diseases. Thus, we have,

$$\begin{aligned} \frac{dS}{dt} &= \Lambda_H - ((1 - u_1)\lambda_{HP} + \mu_H + \lambda_T)S \\ \frac{dI_{HP}}{dt} &= (1 - u_1)\lambda_{HP}S + u_3 r_2^T I_{HA}^P + \lambda_{HP}T_T + \varphi_p \lambda_{HP}R_{HP} - (\phi_1^P + \lambda_T + \mu_H + \delta_{HP})I_{HP} \\ \frac{dP_{HP}}{dt} &= (1 - \theta_1^P)\phi_1^P I_{HP} + u_3 r_3^T P_{HA}^P - (\rho_1^P + \mu_H + \lambda_T)P_{HP} \\ \frac{dR_{HP}}{dt} &= \theta_1^P \phi_1^P I_{HP} + \rho_1^P P_{HP} - (\varphi_p \lambda_{HP} + \mu_H + \lambda_T)R_{HP} \\ \frac{dE_T}{dt} &= (1 - \xi_1^T)\lambda_T(S + R_{HP} + \sigma_T T_T) + \theta_2^P \phi_2^P I_{HE}^P + \rho_2^P P_{HE}^P - (\varepsilon_1^T \lambda_T + \gamma_1^T + \varrho_1^P(1 - u_2)\lambda_{HP} + \mu_H)E_T \\ \frac{dA_T}{dt} &= \xi_1^T \lambda_T(S + R_{HP} + \sigma_T T_T) + \varepsilon_1^T \lambda_T E_T + \gamma_1^T E_T + \theta_3^P \phi_3^P I_{HA}^P + \rho_3^P P_{HA}^P - (r_1^T + \mu_H + \delta_T + \varrho_2^P(1 - u_2)\lambda_{HP})A_T \\ \frac{dT_T}{dt} &= r_1^T A_T - (\sigma_T \lambda_T + \lambda_{HP} + \mu_H)T_T \\ \frac{dI_{HE}^P}{dt} &= (1 - \xi_2^T)\lambda_T I_{HP} + \varrho_1^P(1 - u_2)\lambda_{HP}E_T - (\varepsilon_2^T \lambda_T + \gamma_2^T + \mu_H + \phi_2^P + \delta_{HP1})I_{HE}^P \\ \frac{dI_{HA}^P}{dt} &= \xi_2^T \lambda_T I_{HP} + \varepsilon_2^T \lambda_T I_{HE}^P + \gamma_2^T I_{HE}^P + \varrho_2^P(1 - u_2)\lambda_{HP}A_T - (u_3 r_2^T + \mu_H + \delta_{T1} + \delta_{HP2} + \phi_3^P)I_{HA}^P \\ \frac{dP_{HE}^P}{dt} &= (1 - \xi_3^T)\lambda_T P_{HP} + (1 - \theta_2^P)\phi_2^P I_{HE}^P - (\varepsilon_3^T \lambda_T + \gamma_3^T + \rho_3^P + \mu_H)P_{HE}^P \\ \frac{dP_{HA}^P}{dt} &= \xi_3^T \lambda_T P_{HP} + \varepsilon_3^T \lambda_T P_{HE}^P + \gamma_3^T P_{HE}^P + (1 - \theta_3^P)\phi_3^P I_{HA}^P - (u_3 r_3^T + \delta_{T2} + \rho_3^P + \mu_H)P_{HA}^P \end{aligned} \quad (12)$$

subject to the initial conditions $S(0) = S^0, I_{HP}(0) = I_{HP}^0, P_{HP}(0) = P_{HP}^0, R_{HP}(0) = R_{HP}^0, E_T(0) = E_T^0, A_T(0) = A_T^0, T_T(0) = T_T^0, I_{HE}^P(0) = I_{HE}^{P0}, I_{HA}^P(0) = I_{HA}^{P0}, P_{HE}^P(0) = P_{HE}^{P0}, P_{HA}^P(0) = P_{HA}^{P0}$

with:

$$\begin{aligned} \lambda_{HP} &= \frac{\beta_{HP}[I_{HP} + \eta_p P_{HP} + \kappa_T(I_{HA}^P + \eta_T I_{HE}^P + \eta_p P_{HA}^P + \eta_T \eta_p P_{HE}^P)]}{N_H}, \\ \lambda_T &= \frac{\beta_T[A_T + \omega_p(I_{HA}^P + \eta_p P_{HA}^P)]}{N_H} \end{aligned}$$

The control functions, $u_1(t), u_2(t)$, and $u_3(t)$ are bounded, Lebesgue integrable functions. The control $u_1(t)$ represents the efforts at preventing incident HPV infections. The control $u_2(t)$ aims at preventing infection with HPV by TB infected individuals so as to reduce the co-infection cases. TB Treatment control for individuals dually infected with oncogenic HPV and TB is denoted by $u_3(t)$. The controls u_1 and u_2 satisfies $0 \leq u_1, u_2 \leq 1$ while the control u_3 satisfies $0 < u_3 \leq h$, where h is the TB drug efficacy used for the treatment of co-infected individuals. Our optimal control problem involves a scenario where the number of HPV-infected, TB-infected, the co-infection cases and the cost of implementing preventive and treatment controls $u_1(t), u_2(t)$ and $u_3(t)$ are minimized subject to the state system (12). For this, we consider the

objective functional

$$J[u_1, u_2, u_3] = \int_0^T [I_{HP}(t) + P_{HP}(t) + E_T(t) + A_T(t) + I_{HE}(t) + I_{HA}(t) + P_{HE}(t) + P_{HA}(t) + \frac{\chi_1}{2}u_1^2 + \frac{\chi_2}{2}u_2^2 + \frac{\chi_3}{2}u_3^2] dt \quad (13)$$

T is the final time. We seek to find an optimal control, u_1^*, u_2^*, u_3^* , such that

$$J(u_1^*, u_2^*, u_3^*) = \min\{J(u_1^*, u_2^*, u_3^*) | u_1, u_2, u_3 \in U\} \quad (14)$$

where $U = \{(u_1^*, u_2^*, u_3^*)\}$ such that u_1^*, u_2^*, u_3^* are measurable with $0 \leq u_1^* \leq 1, 0 \leq u_2^* \leq 1, 0 \leq u_3^* \leq r$, for $t \in [0, T]$ is the control set. We shall now establish the existence of such an optimal solution which minimizes the objective functional J .

Theorem 4.1 *Given the objective functional J , defined on the control set U , and subject to the state system (12) with non-negative initial conditions at $t = 0$, then there exists an optimal control triple $u^* = (u_1, u_2, u_3)$ such that $J(u^*) = \min\{J(u_1, u_2, u_3) | u_1, u_2, u_3 \in U\}$.*

We shall prove the existence of the given optimal control u^* , along with the corresponding solution trajectories by following the approach used in Mohammed-Awel and Numfor [18].

Proof:

The state functions are positive and the controls are Lebesgue measurable, therefore we have that $J(u_i) \geq 0$ for all $u_i \in U$.

As a result, $\inf_{u_i \in U} J(u_i)$ exists and is finite. Therefore, a minimizing sequence of controls $(u_i) \in U$ exists such that

$$\lim_{n \rightarrow \infty} J(u_i^n) = \inf_{u_i \in U} J(u_i)$$

Let $S^n, I_{HP}^n, P_{HP}^n, R_{HP}^n, E_T^n, A_T^n, T_T^n, I_{HE}^{pn}, I_{HA}^{pn}, P_{HE}^{pn}, P_{HA}^{pn}$ be the associated state trajectories. Since the state sequences are uniformly bounded, we have that the derivatives are also uniformly bounded. As a result, the state sequences are Lipschitz continuous with the same constant. Applying the Arzela-Ascoli Theorem [13], there exist $S^*, I_{HP}^*, P_{HP}^*, R_{HP}^*, E_T^*, A_T^*, T_T^*, I_{HE}^{p*}, I_{HA}^{p*}, P_{HE}^{p*}, P_{HA}^{p*}$, such that on a sub-sequence

$$(S^n, I_{HP}^n, P_{HP}^n, R_{HP}^n, E_T^n, A_T^n, T_T^n, I_{HE}^{pn}, I_{HA}^{pn}, P_{HE}^{pn}, P_{HA}^{pn}) \rightarrow \xi^* \quad \text{uniformly on } [0, T]$$

where,

$$\xi^* = (S^*, I_{HP}^*, P_{HP}^*, R_{HP}^*, E_T^*, A_T^*, T_T^*, I_{HE}^{p*}, I_{HA}^{p*}, P_{HE}^{p*}, P_{HA}^{p*})$$

Since $\|u_i\|_{L^\infty} < K$ for some $K > 0$, it follows that $u_i \in L^2([0, T])$, such that on a sub-sequence

$$u_i \rightharpoonup u_i^n \quad \text{weakly in } L^2([0, T]), n \rightarrow \infty$$

Applying the lower semi-continuity of L^2 norm with respect to weak convergence, we have that

$$\begin{aligned} \inf_{u_i \in U} J(u_i) &= \lim_{n \rightarrow \infty} J(u_i^n) \\ &= \lim_{n \rightarrow \infty} \int_0^T \left(I_{HP}^n(t) + P_{HP}^n(t) + E_T^n(t) + A_T^n(t) + I_{HE}^{pn}(t) + I_{HA}^{pn}(t) + P_{HE}^{pn}(t) + P_{HA}^{pn}(t) + \frac{\chi_1}{2}(u_1^n)^2 + \frac{\chi_2}{2}(u_2^n)^2 + \frac{\chi_3}{2}(u_3^n)^2 \right) dt \\ &\geq \lim_{n \rightarrow \infty} \int_0^T \left(I_{HP}^*(t) + P_{HP}^*(t) + E_T^*(t) + A_T^*(t) + I_{HE}^{p*}(t) + I_{HA}^{p*}(t) + P_{HE}^{p*}(t) + P_{HA}^{p*}(t) + \frac{\chi_1}{2}(u_1^*)^2 + \frac{\chi_2}{2}(u_2^*)^2 + \frac{\chi_3}{2}(u_3^*)^2 \right) dt \\ &= J(u_i^*) \end{aligned}$$

Considering the convergence of the sequences

$$\{S^n\}_{n=1}^\infty, \{I_{HP}^n\}_{n=1}^\infty, \{P_{HP}^n\}_{n=1}^\infty, \{R_{HP}^n\}_{n=1}^\infty, \{E_T^n\}_{n=1}^\infty, \{A_T^n\}_{n=1}^\infty, \{T_T^n\}_{n=1}^\infty, \{I_{HE}^{pn}\}_{n=1}^\infty, \{I_{HA}^{pn}\}_{n=1}^\infty, \{P_{HE}^{pn}\}_{n=1}^\infty, \{P_{HA}^{pn}\}_{n=1}^\infty$$

and passing to the limit in the ordinary differential equation system (12), we have that $S^*, I_{HP}^*, P_{HP}^*, R_{HP}^*, E_T^*, A_T^*, T_T^*, I_{HE}^{p*}, I_{HA}^{p*}, P_{HE}^{p*}, P_{HA}^{p*}$ are the states corresponding to the control triple (u_i) . Hence, (u_i) is an optimal control triple.

The Pontryagin's Maximum Principle [28] gives the necessary conditions which an optimal control pair must satisfy. This principle transforms (12), (13) and (14) into a problem of minimizing a Hamiltonian, $\mathcal{H}$, pointwisely with regards to the control functions, u_1, u_2, u_3 :

$$\begin{aligned} \mathcal{H} = & I_{HP}(t) + P_{HP}(t) + E_T(t) + A_T(t) + I_{HE}(t) + I_{HA}(t) + P_{HE}(t) + P_{HA}(t) + \frac{\chi_1}{2} u_1^2 + \frac{\chi_2}{2} u_2^2 + \frac{\chi_3}{2} u_3^2 \\ & + \lambda_S [\Lambda_H - ((1 - u_1)\lambda_{HP} + \mu_H + \lambda_T)S] \\ & + \lambda_{I_{HP}} [(1 - u_1)\lambda_{HP}S + u_3 r_2^T I_{HA}^P + \lambda_{HP} T_T + \varphi_P \lambda_{HP} R_{HP} - (\phi_1^P + \lambda_T + \mu_H + \delta_{HP})I_{HP}] \\ & + \lambda_{P_{HP}} [(1 - \theta_1^P)\phi_1^P I_{HP} + u_3 r_3^T P_{HA}^P - (\rho_1^P + \mu_H + \lambda_T)P_{HP}] \\ & + \lambda_{R_{HP}} [\theta_1^P \phi_1^P I_{HP} + \rho_1^P P_{HP} - (\varphi_P \lambda_{HP} + \mu_H + \lambda_T)R_{HP}] \\ & + \lambda_{E_T} [(1 - \xi_1^T)\lambda_T(S + R_{HP} + \sigma_T T_T) + \theta_2^P \phi_2^P I_{HE}^P + \rho_2^P P_{HE}^P - (\varepsilon_1^T \lambda_T + \gamma_1^T + \varrho_1^P(1 - u_2)\lambda_{HP} + \mu_H)E_T] \\ & + \lambda_{A_T} [\xi_1^T \lambda_T(S + R_{HP} + \sigma_T T_T) + \varepsilon_1^T \lambda_T E_T + \gamma_1^T E_T + \theta_3^P \phi_3^P I_{HA}^P + \rho_3^P P_{HA}^P - (r_1^T + \mu_H + \delta_T + \varrho_2^P(1 - u_2)\lambda_{HP})A_T] \\ & + \lambda_{T_T} [r_1^T A_T - (\sigma_T \lambda_T + \lambda_{HP} + \mu_H)T_T] \\ & + \lambda_{I_{HE}^P} [(1 - \xi_2^T)\lambda_T I_{HP} + \varrho_1^P(1 - u_2)\lambda_{HP} E_T - (\varepsilon_2^T \lambda_T + \gamma_2^T + \mu_H + \phi_2^P + \delta_{HP1})I_{HE}^P] \\ & + \lambda_{I_{HA}^P} [\xi_2^T \lambda_T I_{HP} + \varepsilon_2^T \lambda_T I_{HE}^P + \gamma_2^T I_{HE}^P + \varrho_2^P(1 - u_2)\lambda_{HP} A_T - (u_3 r_2^T + \mu_H + \delta_{T1} + \delta_{HP2} + \phi_3^P)I_{HA}^P] \\ & + \lambda_{P_{HE}^P} [\xi_3^T \lambda_T P_{HP} + (1 - \theta_2^P)\phi_2^P I_{HE}^P - (\varepsilon_3^T \lambda_T + \gamma_3^T + \rho_3^P + \mu_H)P_{HE}^P] \\ & + \lambda_{P_{HA}^P} [\xi_3^T \lambda_T P_{HP} + \varepsilon_3^T \lambda_T P_{HE}^P + \gamma_3^T P_{HE}^P + (1 - \theta_3^P)\phi_3^P I_{HA}^P - (u_3 r_3^T + \delta_{T2} + \rho_3^P + \mu_H)P_{HA}^P] \end{aligned} \quad (15)$$

Theorem 4.2 For an optimal control set u_1, u_2, u_3 that minimizes J over U , there are adjoint variables, $\lambda_1, \lambda_2, \dots, \lambda_{11}$ satisfying

$$-\frac{\partial \lambda_i}{\partial t} = \frac{\partial \mathcal{H}}{\partial i}$$

and with transversality conditions

$$\lambda_i(t_f) = 0, \quad \text{where, } i = S, I_{HP}, P_{HP}, R_{HP}, E_T, A_T, T_T, I_{HE}^P, I_{HA}^P, P_{HE}^P, P_{HA}^P. \quad (16)$$

Furthermore,

$$\begin{aligned} u_1^* &= \max \left\{ 0, \min \left(1, \frac{(\lambda_2 - \lambda_1)\beta_{HP}S[I_{HP} + \eta_P P_{HP} + \kappa_T(I_{HA}^P + \eta_T I_{HE}^P + \eta_P P_{HA}^P + \eta_T \eta_P P_{HE}^P)]}{\chi_1 N_H} \right) \right\}, \\ u_2^* &= \max \left\{ 0, \min \left(1, \frac{[(\lambda_9 - \lambda_6)\varrho_2^P A_T + (\lambda_8 - \lambda_5)\varrho_1^P E_T][I_{HP} + \eta_P P_{HP} + \kappa_T(I_{HA}^P + \eta_T I_{HE}^P + \eta_P P_{HA}^P + \eta_T \eta_P P_{HE}^P)]}{\chi_2 N_H} \right) \right\}, \\ u_3^* &= \max \left\{ 0, \min \left(1, \frac{(\lambda_9 - \lambda_2)I_{HA} r_2 + (\lambda_{11} - \lambda_3)P_{HA} r_3}{\chi_3} \right) \right\}, \end{aligned} \quad (17)$$

Proof of Theorem 4.2

Suppose $U^* = (u_1^*, u_2^*, u_3^*)$ is an optimal control and $S^*, I_{HP}^*, P_{HP}^*, R_{HP}^*, E_T^*, A_T^*, T_T^*, I_{HE}^{P*}, I_{HA}^{P*}, P_{HE}^{P*}, P_{HA}^{P*}$ are the corresponding state solutions. Applying the Pontryagin's Maximum Principle [28], there exist adjoint variables satisfying:

$$\begin{aligned} -\frac{d\lambda_S}{dt} &= \frac{\partial \mathcal{H}}{\partial S}, \quad \lambda_S(t_f) = 0, \quad -\frac{d\lambda_{I_{HP}}}{dt} = \frac{\partial \mathcal{H}}{\partial I_{HP}}, \quad \lambda_{I_{HP}}(t_f) = 0, \quad -\frac{d\lambda_{P_{HP}}}{dt} = \frac{\partial \mathcal{H}}{\partial P_{HP}}, \quad \lambda_{P_{HP}}(t_f) = 0, \\ -\frac{d\lambda_{R_{HP}}}{dt} &= \frac{\partial \mathcal{H}}{\partial R_{HP}}, \quad \lambda_{R_{HP}}(t_f) = 0, \quad -\frac{d\lambda_{E_T}}{dt} = \frac{\partial \mathcal{H}}{\partial E_T}, \quad \lambda_{E_T}(t_f) = 0, \quad -\frac{d\lambda_{A_T}}{dt} = \frac{\partial \mathcal{H}}{\partial A_T}, \quad \lambda_{A_T}(t_f) = 0, \\ -\frac{d\lambda_{T_T}}{dt} &= \frac{\partial \mathcal{H}}{\partial T_T}, \quad \lambda_{T_T}(t_f) = 0, \quad -\frac{d\lambda_{I_{HE}^P}}{dt} = \frac{\partial \mathcal{H}}{\partial I_{HE}^P}, \quad \lambda_{I_{HE}^P}(t_f) = 0, \quad -\frac{d\lambda_{I_{HA}^P}}{dt} = \frac{\partial \mathcal{H}}{\partial I_{HA}^P}, \quad \lambda_{I_{HA}^P}(t_f) = 0 \\ -\frac{d\lambda_{P_{HE}^P}}{dt} &= \frac{\partial \mathcal{H}}{\partial P_{HE}^P}, \quad \lambda_{P_{HE}^P}(t_f) = 0, \quad -\frac{d\lambda_{P_{HA}^P}}{dt} = \frac{\partial \mathcal{H}}{\partial P_{HA}^P}, \quad \lambda_{P_{HA}^P}(t_f) = 0 \end{aligned} \quad (18)$$

with transversality conditions;

$$\lambda_S(t_f) = \lambda_{I_{HP}}(t_f) = \lambda_{P_{HP}}(t_f) = \lambda_{R_{HP}}(t_f) = \lambda_{E_T}(t_f) = \lambda_{A_T}(t_f) = \lambda_{T_T}(t_f) = \lambda_{I_{HE}^P}(t_f) = \lambda_{I_{HA}^P}(t_f) = \lambda_{P_{HE}^P}(t_f) = \lambda_{P_{HA}^P}(t_f) = 0$$

We can determine the behaviour of the control by differentiating the Hamiltonian, $\mathcal{H}$ with respect to the controls(u_1, u_2, u_3)

at t . On the interior of the control set, where $0 < u_j < 1$ for all $(j = 1, 2, 3)$, we obtain

$$\begin{aligned} 0 &= \frac{\partial \mathcal{H}}{\partial u_1} = \chi_1 N_H u_1^* - (\lambda_2 - \lambda_1) \beta_{HP} S [I_{HP} + \eta_P P_{HP} + \kappa_T (I_{HA}^P + \eta_T I_{HE}^P + \eta_P P_{HA}^P + \eta_T \eta_P P_{HE}^P)], \\ 0 &= \frac{\partial \mathcal{H}}{\partial u_2} = \chi_2 N_H u_2^* - [(\lambda_9 - \lambda_6) \varrho_2^P A_T + (\lambda_8 - \lambda_5) \varrho_1^P E_T] [I_{HP} + \eta_P P_{HP} + \kappa_T (I_{HA}^P + \eta_T I_{HE}^P + \eta_P P_{HA}^P + \eta_T \eta_P P_{HE}^P)] \\ 0 &= \frac{\partial \mathcal{H}}{\partial u_3} = \chi_3 u_3^* - (\lambda_9 - \lambda_2) I_{HA} r_2 - (\lambda_{11} - \lambda_3) P_{HA} r_3 \end{aligned} \quad (19)$$

Therefore, we have that [14]

$$\begin{aligned} u_1^* &= \frac{(\lambda_2 - \lambda_1) \beta_{HP} S [I_{HP} + \eta_P P_{HP} + \kappa_T (I_{HA}^P + \eta_T I_{HE}^P + \eta_P P_{HA}^P + \eta_T \eta_P P_{HE}^P)]}{\chi_1 N_H}, \\ u_2^* &= \frac{[(\lambda_9 - \lambda_6) \varrho_2^P A_T + (\lambda_8 - \lambda_5) \varrho_1^P E_T] [I_{HP} + \eta_P P_{HP} + \kappa_T (I_{HA}^P + \eta_T I_{HE}^P + \eta_P P_{HA}^P + \eta_T \eta_P P_{HE}^P)]}{\chi_2 N_H}, \\ u_3^* &= \frac{(\lambda_9 - \lambda_2) I_{HA} r_2 + (\lambda_{11} - \lambda_3) P_{HA} r_3}{\chi_3} \end{aligned} \quad (20)$$

$$\begin{aligned} u_1^* &= \max \left\{ 0, \min \left(1, \frac{(\lambda_2 - \lambda_1) \beta_{HP} S [I_{HP} + \eta_P P_{HP} + \kappa_T (I_{HA}^P + \eta_T I_{HE}^P + \eta_P P_{HA}^P + \eta_T \eta_P P_{HE}^P)]}{\chi_1 N_H} \right) \right\}, \\ u_2^* &= \max \left\{ 0, \min \left(1, \frac{[(\lambda_9 - \lambda_6) \varrho_2^P A_T + (\lambda_8 - \lambda_5) \varrho_1^P E_T] [I_{HP} + \eta_P P_{HP} + \kappa_T (I_{HA}^P + \eta_T I_{HE}^P + \eta_P P_{HA}^P + \eta_T \eta_P P_{HE}^P)]}{\chi_2 N_H} \right) \right\}, \\ u_3^* &= \max \left\{ 0, \min \left(1, \frac{(\lambda_9 - \lambda_2) I_{HA} r_2 + (\lambda_{11} - \lambda_3) P_{HA} r_3}{\chi_3} \right) \right\}, \end{aligned} \quad (21)$$

5 Simulations

In this section, we shall explore uncertainty and sensitivity analyses on the parameters of the model due to lack of precision in the estimates of some of the co-infection model parameters and the uncertainty which may occur when gathering data for the simulations. We shall also carry out numerical simulations of the optimal control model (12), in order to assess the impact of different intervention strategies on the dynamics of oncogenic HPV-TB co-infections.

5.1 Uncertainty and sensitivity analyses

The oncogenic HPV-TB co-infection model (1) has thirty nine (39) parameters, and uncertainties are expected to arise in the estimates of their values used in the numerical simulations. Adopting the approach used by Blower and Dowlatabadi [3], we shall carry out a Latin Hypercube Sampling (LHS) on the parameters of the model. For the sensitivity analysis, a Partial Rank Correlation Coefficient (PRCC) was calculated between values of the parameters in the response function and the values of the response function derived from the sensitivity analysis. A total of 1,000 simulations of the co-infection model (1) *per* LHS were run. Using the total number of individuals dually infected with HPV and latent TB (I_{HE}^P) as the response function, the parameters that strongly influence the dynamics of the co-infection model (1) are the demographic parameter, μ_H , the effective contact rate for HPV transmission, β_{HP} , the parameter accounting for increased susceptibility to HPV by TB infected individuals, ϱ_1^P , and the recovery rate from HPV for individuals in I_{HE}^P compartment. Also, using the population of individuals dually infected with HPV and active TB (I_{HA}^P) as the input, the five top ranked parameters are the effective contact rate for HPV transmissibility, β_{HP} , the effective contact rate necessary for TB transmission, β_T , the modification parameter accounting for increased susceptibility to HPV infection by active TB infected individuals, ϱ_2^P , the recovery rate from HPV for individuals in I_{HA}^P compartment and the recovery rate from TB for individuals in I_{HA}^P class. Taking the population of individuals dually infected with persistent HPV and latent TB (P_{HE}^P) as the input, the three top ranked parameters are the effective contact rate for HPV transmissibility, β_{HP} , the fraction of individuals who recover from HPV infection and do not progress to persistent HPV infection, θ_2^P , and the recovery rate from persistent HPV infection, ρ_3^P , for individuals in P_{HE}^P compartment. When the population of individuals dually infected with persistent HPV and active TB is used as the response function, the two top-ranked parameters are the effective contact rate for TB transmission, β_T and the TB treatment rate, r_3^T , for individuals dually infected with persistent HPV and active TB.

Considering the HPV associated basic reproduction number, $\mathcal{R}_{0H}$, as the response function, it is observed in Table 3

that the top four PRCC-ranked parameters are the demographic parameter, μ_H , effective contact rate for HPV transmission, β_{HP} , the fraction of infected individuals who recover from HPV and do not develop persistent HPV, θ_1^P and the recovery rate from HPV ϕ_1^P . Finally, using the TB associated reproduction number, $\mathcal{R}_{0T}$, as the response function the two key parameters that drive the dynamics of the model are the effective contact rate for TB transmission, β_T and the TB treatment rate r_1^T .

Table 3: PRCC values for the co-infection model (1) parameters using the total number of individuals dually infected with: HPV and latent TB (I_{HE}^P), HPV and active TB (I_{HA}^P), Persistent HPV and latent TB (P_{HE}^P), Persistent HPV and active TB (P_{HA}^P), respectively, as well as the associated reproduction numbers $\mathcal{R}_{0H}$ and $\mathcal{R}_{0T}$, as response functions. Parameters which strongly influence the dynamics of the co-infection model with respect to each of the response functions are shown in bold fonts.

Parameters	I_{HE}^P	I_{HA}^P	P_{HE}^P	P_{HA}^P	$\mathcal{R}_{0H}$	$\mathcal{R}_{0T}$
μ_H	-0.4468	-0.1478	-0.3209	0.1208	-0.5074	-0.2068
β_{HP}	0.9304	0.6982	0.6390	0.3300	0.9165	—
β_T	0.3353	0.5813	-0.0719	0.5620	—	0.8182
ϱ_1^P	0.5387	0.0493	0.1298	0.0116	—	—
ϱ_2^P	0.1403	0.5009	0.0683	0.1199	—	—
κ_T	0.1835	0.2371	0.0167	0.0904	—	—
θ_1^P	-0.3717	-0.0286	-0.1216	-0.0579	-0.7015	—
θ_2^P	0.1408	0.0140	-0.7032	-0.0782	—	—
θ_3^P	0.0097	0.0652	0.0233	-0.2433	—	—
ϕ_1^P	-0.1802	-0.0323	-0.0447	-0.0534	-0.8041	—
ϕ_2^P	-0.6866	-0.4079	-0.2726	-0.0732	—	—
ϕ_3^P	0.0394	-0.2870	-0.0175	0.2939	—	—
r_1^T	-0.0480	-0.0471	0.000319	0.1303	—	-0.5629
r_2^T	0.0805	-0.8312	0.2174	0.1088	—	—
r_3^T	0.0477	0.1487	0.3076	-0.8994	—	—
ρ_1^P	-0.0891	0.0035	-0.0376	-0.0340	—	—
ρ_2^P	0.1337	0.0170	0.0631	0.0208	—	—
ρ_3^P	-0.0734	-0.0162	-0.5220	-0.3034	—	—
φ_P	0.0443	-0.0039	0.0061	-0.0184	—	—
δ_{HP}	0.0120	0.0144	0.0208	0.0337	-0.0478	—
δ_{HP1}	0.0220	-0.0026	-0.0104	0.0085	—	—
δ_{HP2}	-0.0418	-0.0033	-0.0214	0.0213	—	—
δ_T	0.0275	-0.0132	0.0270	-0.0041	—	-0.1606
δ_{T1}	0.0016	-0.1478	0.0101	0.0232	—	—
δ_{T2}	0.0097	0.0232	0.0324	-0.1941	—	—
σ_T	0.0062	-0.0006321	0.0229	-0.00886	—	—
ξ_1^T	-0.0687	0.0941	-0.0301	0.0407	—	0.3606
ξ_2^T	0.0377	0.0611	0.3845	0.0232	—	—
ξ_3^T	0.0077	-0.0035	-0.0143	0.0111	—	—
ε_1^T	-0.0116	0.0231	-0.0132	-0.0138	—	—
ε_2^T	0.0052	0.0445	0.0188	0.047	—	—
ε_3^T	0.0058	0.0202	-0.0116	0.0927	—	—
γ_1^T	-0.0297	0.0089	0.049	0.0153	—	0.0793
γ_2^T	-0.0237	0.0842	-0.0314	-0.0003668	—	—
γ_3^T	-0.0127	-0.0199	-0.0326	0.0583	—	—
η_T	0.0731	0.1261	0.0344	0.0318	—	—
η_P	0.1506	0.1929	0.0470	0.1196	—	—
ω_P	0.0475	0.1403	-0.0277	0.1404	—	—

5.2 Numerical simulations

Numerical simulations of the optimal control problem (12), adjoint equations (18) and characterizations of the control (21) are implemented by the Runge Kutta method using the forward backward sweep (carried out in MATLAB). Following the choice of the weight function for HPV vaccination control used in Malik *et al* [17], the balancing factor $\chi_1 = 10^3$. We also assume $\chi_2 = 500$ and $\chi_3 = 400$. The demographic data related to the Shanxi province in rural China is used [8]. We assume the initial conditions to be: $S(0) = 1000, I_{HP}(0) = 300, P_{HP}(0) = 200, R_{HP}(0) = 200, E_T(0) = 600, A_T(0) = 400, T_T(0) = 400, I_{HE}^p(0) = 300, I_{HA}^p(0) = 400, P_{HE}^p(0) = 400, P_{HA}^p(0) = 450$. We implement the following three different control strategies for numerical simulations of the co-infection model (4). **The unit of time is years, throughout the entire simulations.**

- i. Strategy A: Control against incident HPV infection ($u_1 \neq 0$) and control against infection with HPV by TB infected individuals ($u_2 \neq 0$);
- ii. Strategy B: Control against incident HPV infection ($u_1 \neq 0$) and TB treatment control for dually infected individuals ($u_3 \neq 0$);
- iii. Strategy C: control against infection with HPV by TB infected individuals ($u_2 \neq 0$) and TB treatment control for dually infected individuals ($u_3 \neq 0$).

5.2.1 Strategy A: Control against incident HPV infection ($u_1 \neq 0$) and control against infection with HPV by TB infected individuals ($u_2 \neq 0$)

Applying this control strategy, we note that the total number of individuals dually infected with HPV and TB in latent and active stages, respectively, (Figures 2 (a) and 2(b)), and the total number of individuals dually infected with persistent HPV and TB in latent and active stages, respectively (Figures 2(c) and 2(d)) are less when this control is applied than when the control is not applied. To be specific, this control strategy averts almost 420,352 new co-infection cases, which is the greatest number of averted cases in comparison with other control strategies implemented. The control profile for this strategy given in Figure 5, reveals that control u_1 is at its upper bound for the first 3.9 years before ultimately declining to zero. Similarly, the control u_2 is at the maximum value of 90% for the first 8 months before declining to zero at time, $t=4.5$ years.

5.2.2 Strategy B: Control against incident HPV infection ($u_1 \neq 0$) and TB treatment control for dually infected individuals ($u_3 \neq 0$)

The simulations of the total number of dually infected individuals in the presence of TB treatment controls are depicted in Figures 3(a) -3(d). Applying this control, we observe that the total number of individuals dually infected with HPV and TB in latent and active stages of infection respectively, is less than the total population when no control is applied as expected (Figure 3(a) and 3(b)). Similarly, it is noticed from Figures (3(c) and 3(d)), that high population level impact is observed in the total number of individuals dually infected with persistent HPV and TB in latent and active stages of infection, respectively, when this control strategy is applied. Specifically, when this control strategy is implemented, about 300,549 new co-infection cases were averted. The control profile for this strategy presented in Figure 7 shows that control u_1 is at its upper bound for the first 4.0 years before steadily declining to zero at final time. Also, the control u_3 is at the maximum value of 100% for the first 1.2 years and then steadily declines to zero at time, $t=4.5$ years. This simulation results conforms with the epidemiological report in the introduction section that gynaecologic TB is a risk factor for oncogenic HPV infection (and subsequent cancer infection) [37]. Hence, if we focus on TB treatment controls, it can significantly reduce the burden of the co-infection of oncogenic HPV and TB in a population. The simulations are also in line with the point opined by [37], that prior TB infection was associated with persistent HPV and increased susceptibility to cervical cancer. As a result, treating TB infections in dually infected individuals will significantly curb the mixed infections of both diseases.

Figure 2: Plots of the total number of individuals dually infected with HPV and TB in latent and active stages, respectively (Figures 2a and 2b) as well as total number of individuals dually infected with persistent HPV and TB in latent and active stages (Figures 2c and 2d), respectively, the presence of optimal vaccination control against incident HPV infection ($u_1 \neq 0$) and control against infection with HPV by TB infected individuals ($u_2 \neq 0$). Here, $\beta_{HP} = 2.0$, $\beta_T = 8.557$. All other parameters as in Table 2

Figure 3: Plots of the total number of individuals dually infected with HPV and TB in latent and active stages, respectively (Figures 3(a) and 3(b) as well as total number of individuals dually infected with persistent HPV and TB in latent and active stages (Figures 3(c) and 3(d), respectively, the presence of optimal vaccination control against incident HPV infection ($u_1 \neq 0$) and TB treatment control dually infected individuals ($u_3 \neq 0$). Here, $\beta_{HP} = 2.0$, $\beta_T = 8.557$. All other parameters as in Table 2

Figure 4

Figure 5: Combined effects of optimal controls u_1 and u_2 on the dynamics of the co-infection optimal control model (12)

Figure 6

Figure 7: Combined effects of optimal controls u_1 and u_3 on the dynamics of the co-infection optimal control model (12)

Figure 8

Figure 9: Combined effects of optimal controls u_2 and u_3 on the dynamics of the co-infection optimal control model (12)

5.2.3 Strategy C: control against infection with HPV by TB infected individuals ($u_2 \neq 0$) and TB treatment control for dually infected individuals ($u_3 \neq 0$)

Using this control strategy, we observe in Figures 10(a) and 10 (b), that the number of individuals dually infected with HPV and TB in latent and active stages of infection, respectively, is less than the number when no control strategy is applied. Likewise, this strategy has positive population level impact on the populations of infected individuals dually infected with persistent HPV and TB in latent and active stages of infection, respectively, Figures 10(c) and 10 (d). When this intervention strategy is administered, approximately 362,573 new co-infection cases are averted. The control profile for this strategy, depicted by Figure 9 reveals that control u_2 is at its upper bound for the first 4.5 years before gradually falling down to zero at final time. Moreover, the control u_3 is at its minimum value for the first 2.1 years and then steadily rises to its peak value of 100% at time, $t=2.7$ years, before gradually declining to zero at final time. It is imperative to state categorically, that the results of the simulations are based on the parameter values given in table 2 and the initial conditions and weight constants given in Section 5.2

5.3 Cost-effectiveness analysis

The cost-effectiveness analysis is used to evaluate the health interventions related benefits so as to justify the costs of the strategies [4]. This is obtained by comparing the differences among the health outcomes and costs of those interventions; achieved by computing the incremental cost-effectiveness ratio (ICER), which is defined as the cost per health outcome. It is given by:

$$\text{ICER} = \frac{\text{Difference in costs between strategies}}{\text{Difference in health effects between strategies}}.$$

We calculated the total number of co-infection cases averted and the total cost of the strategies applied in Table 4. The total number of co-infection cases prevented is obtained by calculating the total number of individuals when controls are administered and the total number when control is not applied. Similarly, we apply the cost functions $\frac{1}{2}\chi_1 u_1^2$, $\frac{1}{2}\chi_2 u_2^2$, $\frac{1}{2}\chi_3 u_3^2$, over time, to compute the total cost for the various strategies that we implemented. We now compare the cost-effectiveness of strategy B (Optimal HPV vaccination control for sexually active susceptible individuals against incident HPV infection and TB treatment control for dually infected individuals) and strategy C (Control against HPV infection by TB infected

Figure 10: Plots of the total number of individuals dually infected with HPV and TB in latent and active stages, respectively (Figures 10a and 10b) as well as total number of individuals dually infected with persistent HPV and TB in latent and active stages (Figures 10c and 10d), respectively, in the presence of control against HPV infection by TB-infected individuals ($u_2 \neq 0$) and TB treatment control dually infected individuals ($u_3 \neq 0$). Here, $\beta_{HP} = 2.0$, $\beta_T = 8.557$. All other parameters as in Table 2

individuals and TB treatment controls for dually infected individuals).

$$\begin{aligned} \text{ICER (B)} &= \frac{1210}{300,549.2} = 0.004026 \\ \text{ICER (C)} &= \frac{405 - 1210}{362,573.4 - 300,549.2} = -0.01298 \end{aligned}$$

From ICER (B) and ICER(C), we observe a cost saving of 0.01298 observed for strategy C over strategy B. This implies that strategy B strongly dominated strategy C, showing that strategy B is more costly and less effective compared to strategy C. Therefore, strategy B is removed from subsequent ICER computations, shown in Table 5. We shall now compare strategies C and A. Comparing strategy C (Control against HPV infection by TB infected individuals and TB treatment controls

Table 4: Increasing order of the total infection averted due to the control strategies

Strategy	Total infection averted	Total cost	ACER	ICER
B: $u_1(t), u_2(t)$	300, 549.2	1, 210	0.004026	0.004026
C: $u_2(t), u_3(t)$	362, 573.4	405	0.001117	-0.01298
A: $u_1(t), u_2(t)$	420, 352.2	1, 215	0.002890	0.01402

Table 5: Increasing order of the total infection averted due to the control strategies

Strategy	Total infection averted	Total cost	ACER	ICER
C: $u_2(t), u_3(t)$	362, 573.4	405	0.001117	0.001117
A: $u_1(t), u_2(t)$	420, 352.2	1, 215	0.002890	0.01402

for dually infected individuals) and strategy A (Optimal HPV vaccination control for sexually active susceptible individuals

Figure 11

Figure 12: Cost functions of the different control strategies

against incident HPV infection and Control against HPV infection by TB infected individuals), we observe that ICER (A) is greater than ICER (C), showing that strategy A strongly dominated strategy C and is more expensive and less effective compared to strategy C. Consequently, strategy C (the strategy that combines and implements control against HPV infection by TB infected individuals as well as TB treatment controls for dually infected individuals) has the least ICER and is the most cost-effective of all the control strategies for the control and management of oncogenic HPV and TB co-infection. This clearly agrees with the results obtained from ACER method in Table 4 that strategy C is the most cost-effective strategy.

$$\begin{aligned} \text{ICER (C)} &= \frac{405}{362,573.4} = 0.001117 \\ \text{ICER (A)} &= \frac{1215 - 405}{420,352.2 - 362,573.4} = 0.01402 \end{aligned}$$

6 Conclusion

In this work, we have developed and presented a co-infection model for Oncogenic HPV and TB with cost-effectiveness optimal control analysis. The full co-infection model was shown to undergo the phenomenon of backward bifurcation when the associated reproduction number is less than unity. It was further shown that TB and HPV re-infection parameters ($\varphi_P \neq 0$ and $\sigma_T \neq 0$) as well as the exogenous re-infection term ($\varepsilon_1 \neq 0$) induced the phenomenon of backward bifurcation in the oncogenic HPV-TB co-infection model. The global asymptotic stability of the disease-free equilibrium of the co-infection model was also proven **not to exist**, when the associated reproduction number was below unity. The necessary conditions for the existence of optimal control and the optimality system for the co-infection model was established using the Pontryagin's Maximum Principle. Uncertainty and global sensitivity analyses were also carried out to determine the top ranked parameters that influence the dynamics of the co-infection model, when the associated reproduction numbers as well as the infected populations were used as response functions. When the population of individuals dually infected with HPV and latent TB (I_{HE}^P) was used as the response function, the parameters that strongly influence the dynamics of the co-infection model (1) are the demographic parameter, μ_H , the effective contact rate for HPV transmission, β_{HP} , the parameter accounting for increased susceptibility to HPV by TB infected individuals, ϱ_1^P , and the recovery rate from HPV for individuals in I_{HE}^P compartment. In addition, using the population of individuals dually infected with HPV and active TB (I_{HA}^P) as the input, the five top ranked parameters are the effective contact rate for HPV transmissibility, β_{HP} , the effective contact rate necessary for TB transmission, β_T , the modification parameter accounting for increased susceptibility to HPV infection by active TB infected individuals, ϱ_2^P , the recovery rate from HPV for individuals in I_{HA}^P compartment and the

recovery rate from TB for individuals in I_{HA}^P class. Taking the population of individuals dually infected with persistent HPV and active TB as the response function, the two top-ranked parameters are the effective contact rate for TB transmission, β_T and the TB treatment rate, r_3^T , for individuals dually infected with persistent HPV and active TB.

Numerical simulations of the optimal control model showed that:

- i. A combination of HPV prevention control and TB treatment control has a positive population level impact in reducing the burden of oncogenic HPV and TB co-infection cases in a population.
- ii. A strategy that implements control against HPV infection by TB infected individuals and TB treatment controls for dually infected individuals can significantly reduce the burden of oncogenic HPV and TB co-infections.
- iii. The strategy that combines and implements control against HPV infection by TB infected individuals as well as TB treatment control for dually infected individuals has the least ICER and is the most cost-effective of all the control strategies for the control and management of the burden of oncogenic HPV and TB co-infection.

References

- [1] FB Agosto, AI Adekunle, Optimal control of a two-strain tuberculosis-HIV/AIDS co-infection model, *BioSystems*, (2014) (119) 20-24.
- [2] HG Ahmed, SH Bensumaidea, IM Ashankyty, Frequency of human papillomavirus (HPV) subtypes 31, 33, 35, 39 and 45 among Yemeni women with cervical cancer, *Infect. Ag. Cancer* 10 (29) (2015) 1-6.
- [3] SM Blower, H Dowlatabadi, Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example, *International Statistical Review* 2 (1994) 229-243.
- [4] SB Cantor, TG Ganiats, Incremental cost-effectiveness analysis: the optimal strategy depends on the strategy set. *Clin. Epidemiol.* 52 (1999) (6), 517-522.
- [5] C Castillo-Chavez, Z Feng, W Huang, On the computation of R_0 and its role on global stability, in *Mathematical Approaches for Emerging and Reemerging Infectious Diseases: An Introduction* (Minneapolis, MN, 1999), 229-250, IMA Vol. Math. Appl., 125 Springer New York.
- [6] C Castillo-Chavez, B Song, Dynamical models of tuberculosis and their applications, *Math. Biosci. Eng.* 2 (2004) 361-404.
- [7] T Cohen, C Colijin, B Finklea, M Murray, Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission, *J. R. Soc. Interface*, 4 (2007) 523-531.
- [8] China Demographics Profile, 2018, Available at http://www.indexmundi.com/china/demographics_profile. Accessed: 2 May, 2018.
- [9] Fatmawati, H Tasman, Optimal control of HIV resistance and tuberculosis co-infection using treatment intervention, *Asian Pac. J. Trop. Dis.* 7 (2017) 366-373.
- [10] FM Gilbert, I Ihejirika, SC Inyama, A Oname, HI Mbachu, JI Uwakwe, Deterministic Mathematical Model of Tuberculosis Disease with Treatment and Recovered Groups, *International Journal of Mathematics and Statistics Invention* (2019) 7 (1), 47-60
- [11] AO Isere, D Okuonghae, Optimal control model for the outbreak of cholera in Nigeria, *African Journal of Mathematics and Computer Science Research*, 7;24-30; 2014
- [12] A Jemal, F Bray, MM Center, J Ferlay, E Ward, D Forman, Global Cancer Statistics, *CA Cancer J. Clin.* 61 (2011) 69-90.
- [13] J. L. Kelley, General topology, Springer-Verlag, (1991) ISBN 978-0-387-90125-1
- [14] S Lenhart, JT Workman, 2007. Optimal Control Applied to Biological Models. Chapman & Hall, Boca Raton.
- [15] A MacNeil, P Glaziou, C Sismanidis, S Maloney, K Floyd, Global Epidemiology of Tuberculosis and Progress Toward Achieving Global Targets - 2017. *MMWR Morb Mortal Wkly Rep* (2019) 68 263?266 DOI: <http://dx.doi.org/10.15585/mmwr.mm6811a3>
- [16] MT Malik, J Reimer, AB Gumel, EH Elbasha, SM Mahmud, The impact of an imperfect vaccine and pap cytology screening on the transmission of Human Papillomavirus and occurrence of associated cervical dysplasia and cancer, *Math. Biosci. Eng.* 10 (4) (2013).
- [17] T Malik, M Imran, R Jayaraman, Optimal control with multiple human papillomavirus vaccines, *Journal of Theoretical Biology*, (393) 179-193, 2016.
- [18] J Mohammed-Awel, E Numfor, Optimal Insecticide Treated Bednets Coverage and Malaria Treatment in a Malaria-HIV Co-infection Model. *Journal of Biological Dynamics*, 11 (2017) - Issue sup1 : 160-191.
- [19] Z Mukandavire, AB Gumel, W Garira, JM Tchuente, Mathematical Analysis of a Model for HIV-Malaria Co-infection, *Math. Biosci. Eng.* 6 (2) (2009) 333-362.
- [20] KO Okosun, OD Makinde, A co-infection model of malaria and cholera diseases with optimal control, *Math. Biosci.* 258 (2014) 19-32 .
- [21] D Okuonghae, A Korobeinikov, Dynamics of tuberculosis: the effect of direct observation therapy strategy (DOTS) in Nigeria, *Math. Model. Nat. Phenomena*, (2) (2007) 1 99-111.
- [22] D Okuonghae, V Aihie, Case detection and direct observation therapy strategy (DOTS) in Nigeria: its effect on TB dynamics, *J. Biol. Syst.* 16 (1) (2008) 1-31.
- [23] A Oname, RA Umana, D Okuonghae, SC Inyama, Mathematical analysis of a two-sex Human Papillomavirus (HPV) model, *International Journal of Biomathematics*, 11 (2018) (7)

- [24] A Oname, D Okuonghae, RA Umana, SC Inyama, Analysis of a co-infection model for HPV-TB, *Applied Mathematical Modelling*, 77 (2020) 881-901.
- [25] A Oname, D Okuonghae, SC Inyama, A mathematical study of a model for HPV with two high risk strains, in *Mathematics Applied to Engineering, Modelling, and Social Issues Studies in Systems, Decision and Control* (2020) 200, F. Smith, H. Dutta and J. N. Mordeson (eds.)
- [26] A Oname, N Sene, I Nometa, CI Nwakanma, EU Nwafor, NO Iheonu, D Okuonghae, Analysis of COVID-19 and comorbidity co-infection Model with Optimal Control, medRxiv preprint (2020) doi: <https://doi.org/10.1101/2020.08.04.20168013>.
- [27] A Oname, CU Nnanna, SC Inyama, Optimal Control and Cost-effectiveness Analysis of an HPV-Chlamydia Trachomatis co-infection model, medRxiv preprint (2020) doi:<https://doi.org/10.1101/2020.09.07.20190025>.
- [28] LS Pontryagin, VG Boltyanskii, RV Gamkrelidze, EF Mishchenko, *The Mathematical Theory of Optimal Processes*, Wiley, New York, 1962.
- [29] F Saldana, A Korobeinikov, I Barradas, Optimal Control against the Human Papillomavirus: Protection versus Eradication of the Infection, *Abstract and Applied Analysis*, <https://doi.org/10.1155/2019/4567825>
- [30] Shanxi Demographics Data, 2015, Available at <http://www.khoema.com/atlas/china/shanxi> Accessed: 2 May, 2018.
- [31] Tanvi, R Aggarwal, Dynamics of HIV-TB co-infection with detection as optimal intervention strategy, *International Journal of Non-Linear Mechanics* (2020), doi:<https://doi.org/10.1016/j.ijnonlinmec.2019.103388>.
- [32] GT Tilahun, OD Makinde, D Malonza, Co-dynamics of Pneumonia and Typhoid fever diseases with cost effective optimal control analysis, *Appl. Math. Comput.* 316 (2018) 438-459.
- [33] RA Umana, A Oname, SC Inyama, Deterministic and Stochastic Models of the Dynamics of Drug Resistant Tuberculosis; *FUTO Journals Series*, (2016) 2 (2) 173-194.
- [34] JI Uwakwe, SC Inyama, A Oname, Mathematical Model and Optimal Control of New-Castle Disease (ND). *Applied and Computational Mathematics*. (2020) 9 (3) 70-84. doi: 10.11648/j.acm.20200903.14
- [35] P van den Driessche, J Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, *Math. Biosci.* 180 (2002) 29-48.
- [36] World Health Organization. *Global tuberculosis report 2018*. Geneva, Switzerland: World Health Organization; 2018. https://www.who.int/tb/publications/global_report/en
- [37] NM Zetola, S Grover, C Modongo, SP Chiyapo, Collision of three pandemics: The coexistence of cervical cancer, HIV infection, and the prior tuberculosis in the sub-Saharan country of Botswana, *J. Glob. Oncol.* DOI:10.1200/JGO.2015.001701.
- [38] S Zhu, L Xia, S Yu, S Chen, J Zhang, The burden and challenges of tuberculosis in China: findings from the Global Burden of Disease Study 2015, *Nature*, 7 (2017) 14601, DOI:10.1038/s41598-017-15024-1.
- [39] FH Zhao, AP Varanasi, CA Cunningham, BI Graubard, S-Y Hu, F Chen, CJ Barrett, Y-L Qiao, MR Forman, Tuberculosis and oncogenic HPV: Potential co-infections in women at high-risk of cervical cancer in rural China. *Asian P. J. Canc. Prev.* 12 (2011) 1409-1415.